Summary
New imaging techniques and biomarkers are poised to improve the diagnosis of heart failure. The treatment of heart failure with preserved or reduced ejection fraction remains challenging. New drug treatments under investigation are natriuretic peptides, relaxin, ivabradine, spironolactone, and neprilysin. Stem cell therapy in heart failure is an active area of research.
- heart failure
- pulmonary edema
- nesiritide
- acute coronary syndrome
- relaxin
- preserved ejection fraction
- I-PRESERVE study
- brain natriuretic peptide
- stem cell therapy
- STEMI, myocardial infarction
- metaiodobenzylguanidine
- cardiology & cardiovascular medicine clinical trials
- © 2015 SAGE Publications
Tools
Table of contents
Cited By...
- No citing articles found.